Catastrophic antiphospholipid syndrome is a rapidly progressive life-threatening disease that causes multiple organ thromboses and dysfunction in the presence of antiphospholipid antibodies. A high index of clinical suspicion and careful investigation are required to make an early diagnosis so that treatment with anticoagulation and corticosteroids can be initiated; plasma exchange and/or intravenous immunoglobulins can be added if the life-threatening condition persists. Despite aggressive treatment and intensive care unit management, patients with catastrophic antiphospholipid syndrome have a 48% mortality rate, primarily attributable to cardiopulmonary failure. This article reviews the current information on the etiopathogenesis, clinical manifestations, diagnosis, management, and prognosis of catastrophic antiphospholipid syndrome.
Miyakis S, Lockshin MD, Atsumi T, et al.International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost2006;4:295-306.
Piette JC, Cervera R, Levy RA, et al.The catastrophic antiphospholipid syndrome—Asherson’s syndrome. Ann Med Interne (Paris). 2003;154:195-196.
4.
Cervera R, Asherson RA.Multiorgan failure due to rapid occlusive vascular disease in antiphospholipid syndrome: the “catastrophic” antiphospholipid syndrome. APLAR J Rheumatol. 2004;7:254-262.
5.
Westney GE, Harris EN.Catastrophic antiphospholipid syndrome in the intensive care unit. Crit Care Clin. 2002;18: 805-817.
6.
Erkan D, Lockshin MD.What is antiphospholipid syndrome?Curr Rheumatol Rep. 2004;6:451-457.
7.
Rand JH.Molecular pathogenesis of antiphospholipid syndrome. Circ Res. 2002;90:29-37.
8.
Blank M, Asherson RA, Cervera R, et al.Antiphospholipid syndrome infectious origin. J Clin Immunol. 2004;24: 12-23.
9.
Asherson RA, Shoenfeld Y.The role of infection in the pathogenesis of catastrophic antiphospholipid syndrome—molecular mimicry?J Rheumatol. 2000;27:12-14.
10.
Cervera R, Asherson RA, Acevedo ML, et al.Antiphospholipid syndrome associated with infections: clinical and microbi logical characteristics of 100 patients. Ann Rheum Dis. 2004;63:1312-1317.
11.
Asherson RA, Cervera R, Piette JC, et al.Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. Medicine. 2001;80:355-377.
12.
Blank M, Faden D, Tincani A, et al.Immunization with anti-cardiolipin cofactor (β2-glycoprotein-I) induces experimental APS in naive mice. J Autoimmun. 1994;7:441-447.
13.
Blank M, Krause I, Fridkin M, et al.Bacterial induction of autoantibodies to beta2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. J Clin Invest. 2002;109:797-804.
14.
Gharavi AE, Pierangeli SS, Espinola RG, et al.Antiphospholipid antibodies induced in mice by immunization with a cytomegalovirus-derived peptide cause thrombosis and activation of endothelial cells in vivo. Arthritis Rheum. 2002; 46:545-552.
15.
Petri M.Classification and epidemiology of the antiphospholipid syndrome. In: Asherson RA, Cervera R, Piette JC, et al, eds. The Antiphospholipid Syndrome II: Autoimmune Thrombosis. Amsterdam: Elsevier; 2002:11-20.
16.
de Groot PG, Horbach DA, Derksen RH.Protein C and other cofactors involved in the binding of antiphospholipid antibodies: relation to the pathogenesis of thrombosis. Lupus. 1996;5:488-493.
Raschi E, Testoni C, Bosisio D, et al.Role of the MyD88 transduction signaling pathway in endothelial activation by antiphospholipid antibodies. Blood. 2003;101:3495-3500.
19.
Sanchez ML, Katsumata K, Atsumi T, et al.Association of HLA-DM polymorphism with the production of antiphospholipid antibodies. Ann Rheum Dis. 2004;63:1645-1648.
20.
Yasuda S, Atsumi T, Matsuura E, et al.Significance of valine/leucine247 polymorphism of beta2-glycoprotein I in antiphospholipid syndrome: increased reactivity of anti-beta2-glyco-protein I autoantibodies to the valine247 beta2-glycoprotein I variant. Arthritis Rheum. 2005;52:212-218.
21.
Sebastiani GD, Galeazzi M, Tincani A, et al.HLA-DPB1 alleles association of anticardiolipin and anti-beta2GPI antibodies in a large series of European patients with systemic lupus erythematosus. Lupus. 2003;12:560-563.
22.
Hudson M, Herr AL, Rauch J, et al.The presence of multiple prothrombotic risk factors is associated with a higher risk of thrombosis in individuals with anticardiolipin antibodies. J Rheumatol. 2003;30:2385-2391.
23.
Rosendaal FR.Thrombosis in the young: epidemiology and risk factors. A focus on venous thrombosis. Thromb Haemost. 1997; 78:1-6.
24.
Cervera R, Gómez-Puerta JA, Espinosa G, et al.“CAPS Registry”: a review of 200 cases from the International Registry of patients with catastrophic antiphospholipid syndrome (CAPS) [abstract]. Ann Rheum Dis. 2003;62:88.
25.
Kitchens CS.Thrombotic storm: when thrombosis begets thrombosis. Am J Med. 1998;104:381-385.
Cervera R, Font J, Gomez-Puerta JA, et al.Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. Ann Rheum Dis. 2005;64:1205-1209.
28.
Espinosa G, Cervera R, Font J, et al.The lung in the antiphospholipid syndrome. Ann Rheum Dis. 2002;61:195-198.
29.
Wiedermann FJ, Mayr A, Schobersberger W, et al.Acute respiratory failure associated with catastrophic antiphospholipid syndrome. J Intern Med. 2000;247:723-730.
30.
Laterza OF, Nayer H, Jo Bill M, et al.Unusually high concentrations of cTnI and cTnT in a patient with catastrophic antiphospholipid antibody syndrome. Clin Chim Acta. 2003; 337:173-176.
31.
Gunnewiek JM, Van Der Hoeven JG.Cardiac troponin elevations among critically ill patients. Curr Opin Crit Care. 2004; 10:342-346.
32.
Zakynthinos EG, Vassilakopoulos T, Kontogianni DD, et al.A role for transoesophageal echocardiography in the early diagnosis of catastrophic antiphospholipid syndrome. J Intern Med. 2000;248:519-524.
33.
Asherson RA, Cervera R, de Groot PG, et al.Catastrophic Antiphospholipid Syndrome Registry Project Group. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus. 2003;12:530-534.
34.
Wilson WA.Classification criteria for antiphospholipid syndrome. Rheum Dis Clin North Am. 2001;27:499-505.
35.
Drenkard C, Sanchez-Guerrero J, Alarcon-Segovia D.Fall in antiphospholipid antibody at time of thromboocclusive episodes in systemic lupus erythematosus. J Rheumatol. 1989;16:614-617.
36.
Asherson RA, Espinosa G, Cervera R, et al.Catastrophic antiphospholipid syndrome. Proposed guidelines for diagnosis and treatment. J Clin Rheumatol. 2002;8:157-165.
37.
Wahl DG, De Maistre E, Guillemin F, et al.Antibodies against phospholipids and beta 2-glycoprotein I increase the risk of recurrent venous thromboembolism in patients without systemic lupus erythematosus. QJM. 1998;91:125-130.
Wenzel C, Stoiser B, Locker GJ, et al.Frequent development of lupus anticoagulants in critically ill patients treated under intensive care conditions. Crit Care Med. 2002;30:763-770.
40.
Espinosa G, Bucciarelli S, Cervera R, et al.Thrombotic microangiopathic haemolytic anemia and antiphospholipid antibodies. Ann Rheum Dis. 2004;63:730-736.
41.
Amoura Z, Costedoat-Chalumeau N, Veyradier A, et al.Thrombotic thrombocytopenic purpura with severe ADAMTS-13 deficiency in two patients with primary antiphospholipid syndrome. Arthritis Rheum. 2004;50:3260-3264.
42.
Karmochkine M, Mazoyer E, Marcelli A, et al.High prevalence of antiphospholipid antibodies in disseminated intravascular coagulation. Thromb Haemost. 1996;75:971.
43.
Koenig M, Roy M, Baccot S, et al.Thrombotic microangiopathy with liver, gut, and bone infarction (catastrophic antiphospholipid syndrome) associated with HELLP syndrome. Clin Rheumatol. 2004;24:166-168.
44.
Le Thi Thuong D, Tieulie N, Costedoat N, et al.The HELLP syndrome in the antiphospholipid syndrome: retrospective study of 16 cases in 15 women. Ann Rheum Dis. 2005;64: 273-278.
45.
Levy MM, Fink MP, Marshall JC, et al.2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003,31:1250-1256.
46.
George JN, Gilcher RO, Smith JW, et al.Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: diagnosis and management. J Clin Apheresis. 1998;13:120-125.
47.
Burns ER, Lou Y, Pathak A.Morphologic diagnosis of thrombotic thrombocytopenic purpura. Am J Hematol. 2004;75: 18-21.
48.
Smith OP, White B.Infectious purpura fulminans: diagnosis and treatment. Br J Haematol. 1990;104:202-207.
49.
Betrosian AP, Balla M, Papanikolaou M, et al.Meningococcal purpura fulminans in a patient with systemic lupus erythematosus: a mimic for catastrophic antiphospholipid antibody syndrome?Am J Med Sci. 2004;327:373-375.
50.
Campanelli A, Kaya G, Ozsahin AH, et al.Purpura fulminans in a child as a complication of chickenpox infection. Dermatology. 2004;208:262-264.
51.
Cone LA, B Waterbor R, Sofonio MV.Purpura fulminans due to Streptococcus pneumoniae sepsis following gastric bypass. Obes Surg. 2004;14:690-694.
52.
Deshmukh PM, Camp CJ, Rose FB, et al.Capnocytophaga canimorsus sepsis with purpura fulminans and symmetrical gangrene following a dog bite in a shelter employee. Am J Med Sci. 2004;327:369-372.
53.
Warkentin TE, Greinacher A.Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 suppl):311S-337S.
54.
Stanton PE Jr, Evans JR, Lefemine AA, et al.White clot syndrome. South Med J. 1988;81:616-620.
55.
Martinuzzo ME, Forastiero RR, Adamczuk Y, et al.Antiplatelet factor 4—heparin antibodies in patients with antiphospholipid antibodies. Thromb Res. 1999;95:271-279.
56.
Gruel Y.Antiphospholipid syndrome and heparin-induced thrombocytopenia: update on similarities and differences. J Autoimmun. 2000;15:265-268.
57.
Erkan D, Asherson RA, Cervera R, et al.Plasma exchange or intravenous immunoglobulins in catastrophic antiphospholipid syndrome. In: 7th International Lupus Congress Abstract Book. New York: 2004:M24A.
58.
Amital H, Levy Y, Davidson C, et al.Catastrophic antiphospholipid syndrome: remission following leg amputation in 2 cases. Semin Arthritis Rheum. 2001;31:127-132.
59.
The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000;342:1301-1308.
60.
Drakulovic MB, Torres A, Bauer TT, et al: Supine body position as a risk factor for nosocomial pneumonia in mechanically ventilated patients: A randomised trial. Lancet. 1999; 354:1851-1858.
61.
Schweickert WD, Gehlbach BK, Pohlman AS, et al.Daily interruption of sedative infusions and complications of critical illness in mechanically ventilated patients. Crit Care Med. 2004;32:1272-1276.
62.
Ely EW, Meade MO, Haponik EF, et al: Mechanical ventilator weaning protocols driven by nonphysician health-care professionals: Evidence-based clinical practice guidelines. Chest. 2001;120:454S-463S.
63.
Van den Berghe G.How does blood glucose control with insulin save lives in intensive care?J Clin Invest. 2004;114: 1187-1195.
64.
Cook DJ, Witt LG, Cook RJ, et al: Stress ulcer prophylaxis in the critically ill: a meta-analysis. Am J Med. 1991;91:519-527.
65.
Dellinger RP, Carlet JM, Masur H, et al: Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med. 2004;32:858-873.
66.
Espinosa G, Cervera R, Font J, et al.Adrenal involvement in the antiphospholipid syndrome. Lupus. 2003;12:569-572.
67.
Annane D.Time for a consensus definition of corticosteroid insufficiency in critically ill patients. Crit Care Med. 2003;31: 1868-1869.
68.
Erkan D, Asherson RA, Espinosa G, et al.Long term outcome of catastrophic antiphospholipid syndrome survivors. Ann Rheum Dis. 2003;62:530-533.
69.
Erkan D, Leibowitz E, Berman J, et al.Perioperative medical management of antiphospholipid syndrome: hospital for special surgery experience, review of literature, and recommendations. J Rheumatol. 2002;29:843-849.
70.
Burcoglu-O’Ral A, Erkan D, Asherson R.Treatment of catastrophic antiphospholipid syndrome with defibrotide, a proposed vascular endothelial cell modulator. J Rheumatol. 2002;29:2006-2011.
71.
Ehresmann S, Arkfeld D, Shinada S, et al.A novel therapeutic approach for catastrophic antiphospholipid syndrome (CAPS) when conventional therapy with anticoagulants and steroids were unsuccessful [abstract]. Ann Rheum Dis. 2004;64 (suppl):FR10278.
72.
Ozaki M, Ogata M, Yokoyama T, et al.Prevention of thrombosis with prostaglandin E1 in a patient with catastrophic antiphospholipid syndrome. Can J Anaesth. 2005;52:143-147.
73.
Weitz JI, Hirsh J, Samama MM.New anticoagulant drugs: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 suppl):265S-286S.
74.
Cowchock S.Prevention of fetal death in the antiphospholipid antibody syndrome. Lupus. 1996;5:467-472.
75.
Girardi G, Redecha P, Salmon JE.Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med. 2004;10:1222-1226.
76.
Scheinman RI, Cogswell PC, Lofquist AK, et al.Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science. 1995;270: 283-286.
77.
Auphan N, DiDonato JA, Rosette C, et al.Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science. 1995;270:286-290.
78.
Lasa M, Brook M, Saklatvala J, et al.Dexamethasone destabilizes cyclooxygenase 2 mRNA by inhibiting mitogen-activated protein kinase p38. Mol Cell Biol. 2001;21:771-780.
79.
Christman JW, Lancaster LH, Blackwell TS.Nuclear factor kappa B: a pivotal role in the systemic inflammatory response syndrome and new target for therapy. Intensive Care Med. 1998;24:1131-1138.
80.
Erkan D, Cervera R, Asherson RA.Catastrophic antiphospholipid syndrome: where do we stand?Arthritis Rheum. 2003;48: 3320-3327.
81.
Knezevic-Maramica I, Kruskall MS.Intravenous immune globulins: an update for clinicians. Transfusion. 2003;43: 1460-1480.
82.
Sherer Y, Levy Y, Shoenfeld Y.Intravenous immunoglobulin therapy of antiphospholipid syndrome. Rheumatology. 2000; 39:421-426.
83.
Bayry J, Lacroix-Desmazes S, Kazatchkine MD, et al.Intravenous immunoglobulin for infectious diseases: back to the pre-antibiotic and passive prophylaxis era?Trends Pharmacol Sci. 2004;25:306-310.
84.
Chapman SA, Gilkerson KL, Davin TD, et al.Acute renal failure and intravenous immune globulin: occurs with sucrose-stabilized, but not with D-sorbitol-stabilized, formulation. Ann Pharmacother. 2004;38:2059-2067.
Erkan D, Asherson RA, Cervera R, et al.Reply to the “letter to the editor” by Jean et al (Intravenous immunoglobulins and antiphospholipid syndrome: comment on the article by Erkan et al). Arthritis Rheum. 2004;50:2711-2713.
87.
Flamholz R, Tran T, Grad GI, et al.Therapeutic plasma exchange for the acute management of the catastrophic antiphospholipid syndrome: beta (2)-glycoprotein I antibodies as a marker of response to therapy. J Clin Apheresis. 1999;14:171-176.
88.
Wallace DJ.Apheresis for lupus erythematosus: state of the art. Lupus. 2001;10:193-196.
89.
Kane D, McSweeney F, Swan N, et al.Catastrophic antiphospholipid antibody syndrome in primary systemic sclerosis. J Rheumatol. 1998;25:810-812.
90.
Kovacs IB, Mayou SC, Kirby JD.Infusion of a stable prostacyclin analogue, iloprost, to patients with peripheral vascular disease: lack of antiplatelet effect but risk of thromboembolism. Am J Med. 1991;90:41-46.
91.
Tedeschi A, Meroni PL, Del Papa N, et al.Thrombotic events in patients with systemic sclerosis treated with iloprost. Arthritis Rheum. 1998;41:559-560.
92.
Zwissler B, Kemming G, Habler O, et al.Inhaled prostacyclin (PGI2) versus inhaled nitric oxide in adult respiratory distress syndrome. Am J Respir Crit Care Med. 1996;154:1671-1677.
93.
Dosekun AK, Pollak VE, Glas-Greenwalt P, et al.Ancrod in systemic lupus erythematosus with thrombosis. Clinical and fibrinolysis effects. Arch Intern Med. 1984;144:37-42.
94.
Falanga A, Vignoli A, Marchetti M, et al.Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells. Leukemia. 2003;17:1636-1642.
95.
Erdozain JG, Ruiz-Irastorza G, Egurbide MV, et al.Sustained response to rituximab of autoimmune hemolytic anemia associated with antiphospholipid syndrome. Haematologica. 2004;89: ECR34.
96.
Crowther MA, Ginsberg JS, Julian J, et al.A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003;349:1133-1138.
97.
de Groot PG, Horbach DA, Derksen RH.Protein C and other cofactors involved in the binding of antiphospholipid antibodies: relation to the pathogenesis of thrombosis. Lupus. 1996;5:488-493.
98.
Opal SM, Esmon CT.Bench-to-bedside review: functional relationships between coagulation and the innate immune response and their respective roles in the pathogenesis of sepsis. Crit Care. 2003;7:23-38.
99.
Yan SB, Helterbrand JD, Hartman DL, et al: Low levels of protein C are associated with poor outcome in severe sepsis. Chest. 2001;120:915-922.
100.
Matthay MA, Ware LB.Plasma protein C levels in patients with acute lung injury: prognostic significance. Crit Care Med. 2004;32(5 suppl):S229-S232.
101.
Bernard GR, Vincent JL, Laterre PF, et al: Efficacy and safety of recombinant human APC for severe sepsis. N Engl J Med. 2001;344:699-709.
102.
Meroni PL, Raschi E, Testoni C, et al.Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum. 2001;44:2870-2878.
103.
Ferrara DE, Liu X, Espinola RG, et al.Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model. Arthritis Rheum. 2003;48:3272-3279.
104.
Ferrara DE, Swerlick R, Casper K, et al.Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells. J Thromb Haemost. 2004; 2:1558-1563.
105.
Mullenix PS, Andersen CA, Starnes BW.Atherosclerosis as inflammation. Ann Vasc Surg. 2005;19:130-138.
106.
Kinlay S, Schwartz GG, Olsson AG, et al.Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering Study Investigators. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation. 2003;108: 1560-1566.
